100 years of Mycobacterium bovis bacille Calmette-Guérin

Christoph Lange, Peter Aaby, Marcel A Behr, Peter R Donald, Stefan H E Kaufmann, Mihai G Netea, Anna M Mandalakas

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


Mycobacterium bovis bacille Calmette-Guérin (BCG), an experimental vaccine designed to protect cattle from bovine tuberculosis, was administered for the first time to a newborn baby in Paris in 1921. Over the past century, BCG has saved tens of millions of lives and has been given to more humans than any other vaccine. It remains the sole tuberculosis vaccine licensed for use in humans. BCG provides long-lasting strong protection against miliary and meningeal tuberculosis in children, but it is less effective for the prevention of pulmonary tuberculosis, especially in adults. Evidence mainly from the past two decades suggests that BCG has non-specific benefits against non-tuberculous infections in newborn babies and in older adults, and offers immunotherapeutic benefit in certain malignancies such as non-muscle invasive bladder cancer. However, as a live attenuated vaccine, BCG can cause localised or disseminated infections in immunocompromised hosts, which can also occur following intravesical installation of BCG for the treatment of bladder cancer. The legacy of BCG includes fundamental discoveries about tuberculosis-specific and non-specific immunity and the demonstration that tuberculosis is a vaccine-preventable disease, providing a foundation for new vaccines to hasten tuberculosis elimination.

TidsskriftThe Lancet Infectious Diseases
Udgave nummer1
Sider (fra-til)e2-e12
StatusUdgivet - jan. 2022

Bibliografisk note

Copyright © 2022 Elsevier Ltd. All rights reserved.


Dyk ned i forskningsemnerne om '100 years of Mycobacterium bovis bacille Calmette-Guérin'. Sammen danner de et unikt fingeraftryk.